Lyon, 21 March 2018 – THERANEXUS, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates acting on the interaction between neurons and glial cells, today announces the results for a clinical pharmacokinetic study of the glial modulator, THN01, a component of its drug candidates THN201 and THN101. The objective of the study was to determine the dose to be administered to achieve the target plasma exposure and to be able to make progress in the manufacture of pharmaceutical batches for clinical research programmes on the two drug candidates.
“We are very pleased with the results of this pharmacokinetics study, which means we can go on with our clinical development plan this year for our drug candidates THN201 and THN101” explains Werner Rein, medical director at Theranexus.
With its unique breakthrough approach, Theranexus aims to meet the medical needs of patients in 4 indications including Alzheimer's disease (THN201) and neuropathic pain (THN101).
The drug candidate THN201 is designed to treat neurocognitive disorders associated with Alzheimer's disease. It consists of a combination of donepezil, the first line treatment for this disease, and low dose mefloquine acting on the activity of the glial cells. This drug candidate continues its specific clinical development in 2018. The neurocognitive disorders in the form of memory loss, reasoning and orientation problems, affect 37 million patients in G20 countries. Prevalence increases as the population ages and it is one of the main causes of dependence of the elderly.
The drug candidate THN101 aims to improve treatment of neuropathic pain. In the same way, it consists of a combination of the first line treatment for this type of pain, amitriptyline, and mefloquine, again at a low dose. This drug candidate also continues its specific clinical development in 2018. Neuropathic pain is generally caused by damage to the nervous system. To date, 100 causes are listed (phantom limb pain, post-chemotherapy pain etc.) and they affect almost 70 million people in Europe, the United States and Japan alone.
Financial and Administrative Director
ACTUS finance & communication
Caroline Lesage / Théo Martin
+33 (0)1 53 67 36 79 / +33 (0)1 53 67 36 75
+ 33 (0)6 07 76 82 83
 Narcolepsy, Parkinson's disease, Alzheimer's disease and neuropathic pain.